Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
2
×
biotech
clinical trials
life sciences
national blog main
abaloparatide
alirocumab
alnylam pharmaceuticals
boston blog main
drugs
europe blog main
europe top stories
european commission
evercore isi
evolocumab
fda
heart attack
inclisiran
joseph swartz
medicines co.
national
new york
new york blog main
new york top stories
osteoporosis
pcsk9 inhibitors
radius health
regeneron pharmaceuticals
rna interference
romosozumab
san francisco blog main
san francisco top stories
stroke
svb leerink
teriparatide
ucb
umer raffat
What
drug
2
×
heart
2
×
alnylam
amgen
amgen’s
approval
based
carries
cholesterol
data
developed
europe
european
evidence
lasting
long
looms
lowering
marketing
medco
medicine
medicines
new
nod
osteoporosis
partner
pharmaceuticals
presented
raise
reckoning
risk
rna
supporting
term
touts
use
warning
wins
Language
unset
Current search:
drug
×
amgen
×
heart
×
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
